Mucopolysaccharidosis Type I in Mexico: Case-Based Review

被引:4
作者
Cantu-Reyna, Consuelo [1 ,2 ,3 ]
Vazquez-Cantu, Diana Laura [2 ]
Cruz-Camino, Hector [1 ,2 ]
Narvaez-Diaz, Yuriria Arlette [3 ]
Flores-Caloca, Oscar [3 ]
Gonzalez-Llano, Oscar [1 ,3 ]
Araiza-Lozano, Carolina [2 ]
Gomez-Gutierrez, Rene [1 ,2 ]
机构
[1] Tecnol Monterrey, Escuela Med & Ciencias Salud, Monterrey 64710, Mexico
[2] Genomi k, Med Dept, Monterrey 64060, Mexico
[3] ISSSTELEON, Ctr Med, Monterrey 64000, Mexico
来源
CHILDREN-BASEL | 2023年 / 10卷 / 04期
关键词
Mucopolysaccharidosis I; Mexico; iduronidase; HEMATOPOIETIC-CELL TRANSPLANTATION; ENZYME REPLACEMENT; THERAPY; IDENTIFICATION; COMBINATION; MANAGEMENT; MUTATIONS; PHENOTYPE; EFFICACY; DISEASE;
D O I
10.3390/children10040642
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Introduction: Mucopolysaccharidosis type I (MPS I) is a lysosomal storage disease present in 1:100,000 newborns. Variants in the IDUA (alpha-L-iduronidase) gene decrease the enzyme activity for glycosaminoglycans metabolism. MPS I patients exhibit clinical manifestations that fall on the Hurler, Hurler-Scheie, and Scheie syndrome spectrum. Case presentation: We present a male Mexican patient with respiratory exacerbations requiring recurrent hospitalizations. He showed macrocephaly, coarse facies, hepatomegaly, umbilical hernia, and dorsal kyphosis. The sequencing of the IDUA gene revealed the following genotype: c.46_57del12/c.1205G>A. He received combined therapy with hematopoietic stem cell transplantation and enzyme replacement. Mexican case reports were analyzed to estimate the prevalence of the associated genetic variants. Conclusion: Despite the challenges of managing this rare disease in Mexico, our patient benefited from the combined therapy. The discrete clinical manifestations and prompt evaluation by a geneticist were crucial in establishing a diagnosis, enabling an early intervention by a multidisciplinary team. The combination of ERT before and after HSCT provided health benefits to our patient.
引用
收藏
页数:9
相关论文
共 27 条
[1]   Marrow stromal cells from patients affected by MPS I differentially support haematopoietic progenitor cell development [J].
Baxter, MA ;
Wynn, RF ;
Schyma, L ;
Holmes, DK ;
Wraith, JE ;
Fairbairn, LJ ;
Bellantuono, I .
JOURNAL OF INHERITED METABOLIC DISEASE, 2005, 28 (06) :1045-1053
[2]   The natural history of MPS I: global perspectives from the MPS I Registry [J].
Beck, Michael ;
Arn, Pamela ;
Giugliani, Roberto ;
Muenzer, Joseph ;
Okuyama, Torayuki ;
Taylor, John ;
Fallet, Shari .
GENETICS IN MEDICINE, 2014, 16 (10) :759-765
[3]  
Beesley CE, 2001, HUM GENET, V109, P503
[4]   IDUA Mutational Profiling of a Cohort of 102 European Patients with Mucopolysaccharidosis Type I: Identification and Characterization of 35 Novel α-L-iduronidase (IDUA) Alleles [J].
Bertola, Francesca ;
Filocamo, Mirella ;
Casati, Giorgio ;
Mort, Matthew ;
Rosano, Camillo ;
Tylki-Szymanska, Anna ;
Tuysuz, Beyhan ;
Gabrielli, Orazio ;
Grossi, Serena ;
Scarpa, Maurizio ;
Parenti, Giancarlo ;
Antuzzi, Daniela ;
Dalmau, Jaime ;
Di Rocco, Maja ;
Vici, Carlo Dionisi ;
Okur, Ilyas ;
Rosell, Jordi ;
Rovelli, Attilio ;
Furlan, Francesca ;
Rigoldi, Miriam ;
Biondi, Andrea ;
Cooper, David N. ;
Parini, Rossella .
HUMAN MUTATION, 2011, 32 (06) :E2189-E2210
[5]   Genotype-phenotype relationships in mucopolysaccharidosis type I (MPS I): Insights from the International MPS I Registry [J].
Clarke, Lorne A. ;
Giugliani, Roberto ;
Guffon, Nathalie ;
Jones, Simon A. ;
Keenan, Hillary A. ;
Munoz-Rojas, Maria, V ;
Okuyama, Torayuki ;
Viskochil, David ;
Whitley, Chester B. ;
Wijburg, Frits A. ;
Muenzer, Joseph .
CLINICAL GENETICS, 2019, 96 (04) :281-289
[6]   Mucopolysaccharidosis Type I Newborn Screening: Best Practices for Diagnosis and Management [J].
Clarke, Lorne A. ;
Atherton, Andrea M. ;
Burton, Barbara K. ;
Day-Salvatore, Debra L. ;
Kaplan, Paige ;
Leslie, Nancy D. ;
Scott, C. Ronald ;
Stockton, David W. ;
Thomas, Janet A. ;
Muenzer, Joseph .
JOURNAL OF PEDIATRICS, 2017, 182 :363-370
[7]   Enzyme replacement therapy and/or hematopoietic stem cell transplantation at diagnosis in patients with mucopolysaccharidosis type I: results of a European consensus procedure [J].
de Ru, Minke H. ;
Boelens, Jaap J. ;
Das, Anibh M. ;
Jones, Simon A. ;
van der Lee, Johanna H. ;
Mahlaoui, Nizar ;
Mengel, Eugen ;
Offringa, Martin ;
O'Meara, Anne ;
Parini, Rossella ;
Rovelli, Attilio ;
Sykora, Karl-Walter ;
Valayannopoulos, Vassili ;
Vellodi, Ashok ;
Wynn, Robert F. ;
Wijburg, Frits A. .
ORPHANET JOURNAL OF RARE DISEASES, 2011, 6
[8]  
Mendoza-Ruvalcaba SD, 2020, GENET MOL BIOL, V43, DOI [10.1590/1678-4685-GMB-2018-0347, 10.1590/1678-4685-gmb-2018-0347]
[9]   Efficacy and safety of intravenous laronidase for mucopolysaccharidosis type I: A systematic review and meta-analysis [J].
Dornelles, Alicia Dorneles ;
Artigalas, Osvaldo ;
da Silva, Andre Anjos ;
Vallejo Ardila, Dora Lucia ;
Alegra, Taciane ;
Pereira, Tiago Veiga ;
Pinto e Vairo, Filippo ;
Doederlein Schwartz, Ida Vanessa .
PLOS ONE, 2017, 12 (08)
[10]   Gaucher's Disease and Hurler's Syndrome in Two First Cousins [J].
Fenton-Navarro, Patricia ;
Perez-Campos, Eduardo ;
del Socorro Pina-Canseco, Maria ;
Fenton-Navarro, Bertha .
INTERNATIONAL JOURNAL OF HUMAN GENETICS, 2017, 17 (03) :109-117